Capsida Biotherapeutics Inc. presented preclinical data for a new next-generation gene supplementation therapy candidate, CAP-003, for Parkinson’s disease (PD) patients with GBA1 mutations (PD-GBA).

Ubiquigent Ltd. has announced a strategic partnership with Alleo Labs Corp. to advance deubiquitinase (DUB)-focused preclinical programs.

Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It was demonstrated that NTX-101 bound both chemically and synthetically nitrated α-Syn (n-Syn), with no binding to non-nitrated α-Syn or an irrelevant nitrated protein observed.

Graft Polymer (UK) plc has announced a research agreement between its partner, Awakn Life Sciences Corp., and the University of Nottingham. The agreement covers in vivo research to evaluate the potential of Graft Polymer and Awakn’s aminoindane NCE co-lead series to enhance social cognition and pro-social behaviors.

Researchers from Harvard Medical School and the Icahn School of Medicine at Mount Sinai found two rare, recurrent patterns of mutation in the post-mortem brain tissue of individuals with schizophrenia that could reflect prenatal mutational processes.

Marvel Biosciences Corp. and its wholly owned subsidiary Marvel Biotechnology Inc. have reported promising results from a recent study of MB-204 in the Oprm1 mouse model of autism, showing that just 1 hour after administering a single oral dose of MB-204, the drug successfully reversed the social behavior deficits typically seen in the model.

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance small molecules it says can degrade multiple types of harmful proteins. Rather than tagging single disease proteins with a ubiquitin marker for degrading via 26S proteasomes, these compounds directly activate 20S proteasomes that naturally recognize disordered proteins without the need for ubiquitin tagging.